retatrutide type 2 diabetes phase 2 results 2024 ada More data on dropped today at the conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Retatrutide Dosing Guide: 1-12 mg

An update on the safety of SGLT2 inhibitors

For many users, this model speeds appropriate care and reduces unnecessary travel to clinics or emergency rooms

At The Stoehr Center, we see weight loss injections as the spark to get you started, not the whole solution

The targeted fasting plasma glucose goal was achieved in 35% of patients in both groups at 30 weeks

Food and Drug Administrations Pharmacy Compounding Advisory Committee will meet July 23 and 24 to review whether seven peptides should be eligible for compounding under Section 503A of the Federal Food, Drug and Cosmetic Act

These probiotics work with the natural GLP-1 fibers, help improve digestion and maximize the efficacy of GLP-1 production